Are Weight Loss Medications Safe to Take Long-Term?

by Burst Health

"Is it safe to take long-term?" is one of the most common questions patients raise about weight loss medication. The honest answer is that long-term safety is not a single fact about a medication. It is the result of ongoing clinical review for the individual patient, supported by a national surveillance system that watches medicines across the broader population. This article explains how that system works in Australia and what ongoing review tends to look like in practice.

This article is general information only. It does not make a safety claim about any specific medication. The Consumer Medicine Information leaflet for a particular medication, and the prescribing practitioner, are the authoritative sources of safety information for that medication. Decisions about long-term use are clinical decisions, not decisions a webpage can make.

The Regulatory Framework for Ongoing Safety in Australia

In Australia, the Therapeutic Goods Administration is responsible for the safety, quality, and efficacy of medicines. Before a medication can be supplied, it must be evaluated and entered on the Australian Register of Therapeutic Goods. That initial evaluation is only the first step. Once a medication is in use, it is subject to ongoing post-market surveillance. The post-market surveillance system has several connected components:

  • Sponsor obligations. Companies that supply medicines in Australia are required to monitor their products, submit periodic safety update reports to the TGA, and report serious adverse events promptly.

  • The Database of Adverse Event Notifications (DAEN). A public database of adverse event reports, published in de-identified form so that healthcare professionals and the public can search the available signals.

  • The Black Triangle Scheme. A scheme by which new prescription medicines, or medicines being used in new ways, are flagged with a black triangle symbol on Consumer Medicine Information and Product Information documents to indicate that they are under additional monitoring.

  • Updated Consumer Medicine Information and Product Information. The documents that accompany every prescription medicine in Australia are updated as new safety information emerges. The TGA publishes the current versions at tga.gov.au.

  • Regulatory action. Where a safety signal warrants it, the TGA can change the conditions under which a medicine is supplied, update prescribing guidance, require label changes, or in serious cases withdraw a medicine from the market.

This system is the reason the safety profile of a medication can evolve over time. A medication that has been on the market for many years has accumulated more real-world safety data than one that has only been available for a short time. That accumulation is part of how long-term safety is built up.

Why "Long-Term" Is Defined Differently for Different Medications

There is no single definition of "long-term" that applies to every weight loss medication. Each medication has been studied for specific durations as part of its registration, and clinical practice has built up around those evidence bases over time. Practitioners use the available evidence to:

  • understand what is known about safety over the duration that has been studied

  • understand the limits of what is known beyond that duration

  • weigh those considerations against the patient's clinical situation

For some medications, long-term use is well established in clinical practice, with decades of post-market experience. For others, the evidence base is more recent and is still expanding. A practitioner will be aware of the position for a specific medication and will discuss it with the patient.

How Real-World Evidence Adds to the Picture

Beyond the data collected at the point of registration, the picture of a medication's long-term safety is built up from real-world experience. Several sources feed into this picture:

  • ongoing clinical trials, including long-duration follow-up of patients who took part in earlier trials

  • registry studies, in which patients who take a medication are followed over time and their outcomes recorded

  • adverse event reports submitted through the Australian pharmacovigilance system and equivalent systems internationally

  • post-marketing safety studies required by regulators as a condition of approval

  • analyses of routinely collected health data, including pharmacy dispensing records

Each source has its strengths and its limits. Taken together, they allow regulators, clinicians, and researchers to refine the safety picture over time. This is why prescribers stay current with safety advice rather than relying solely on the information available at the time a medication was first listed.

Monitoring as a Clinical Decision

Monitoring is what makes ongoing use a clinical process rather than a static prescription. A practitioner will typically agree a schedule of follow-up appointments and reviews that reflects:

  • the medication

  • the patient's underlying conditions

  • the patient's response to treatment

  • any side effects experienced

  • changes in the patient's overall health

The exact schedule is medication-specific and patient-specific. Some patients will be reviewed more often than others. The point of these reviews is not paperwork. They are the mechanism by which the plan is kept appropriate for the patient over time.

What Ongoing Reviews Typically Involve

While the detail depends on the specific situation, ongoing reviews for a patient on prescription weight loss medication often include:

  • a conversation about how the patient is feeling and any side effects experienced

  • an assessment of progress against the patient's clinical goals

  • a review of weight, waist circumference, and other relevant measurements

  • pathology where clinically appropriate, including glucose, glycated haemoglobin (HbA1c), lipid profile, liver function, kidney function, and other tests as indicated

  • a review of other medications and any changes to them

  • a discussion of lifestyle, dietary, and behavioural elements of the plan

  • an updated decision about whether to continue, change, or stop the medication

The review is also the point at which questions, concerns, and changes in the patient's life can be brought into the plan. Patients are encouraged to come to reviews with the information and questions they have, rather than save them for between appointments.

The Role of Pharmacovigilance Reporting

Pharmacovigilance is the formal term for the system that monitors the safety of medicines after they are in use. In Australia, it is supported by:

  • the TGA's Database of Adverse Event Notifications, into which patients and clinicians can report side effects

  • the black triangle symbol used to mark medications under additional monitoring

  • NPS MedicineWise, which runs medicines information services and supports quality use of medicines

  • routine review of safety data, both nationally and internationally, which can lead to updated Consumer Medicine Information leaflets, prescribing guidance, and clinician communications

  • sponsor reporting requirements, including periodic safety update reports

This system is not abstract. The information it produces feeds back into Consumer Medicine Information leaflets, prescribing guidance, and clinician training. It is one of the reasons safety knowledge for a medication can improve over time, even when a medication has been on the market for years.

Stopping, Changing, or Continuing Treatment

Decisions to stop, change, or continue weight loss medication are clinical decisions. They are made by the practitioner in conversation with the patient, based on:

  • how the patient is responding

  • the side effects being experienced

  • the patient's broader health

  • the relevant clinical evidence

  • the patient's preferences and circumstances

Stopping a medication abruptly without medical advice can be a problem for some medications. Continuing a medication beyond the point at which it is appropriate can also be a problem. Both decisions are part of the practitioner's role, in partnership with the patient.

When a medication is stopped or changed, the broader plan around lifestyle, dietary, and behavioural support continues to matter. Australian clinical thinking treats weight management as a long-term process, and obesity is increasingly understood as a chronic relapsing condition that benefits from continuity of care.

The Patient's Role in Ongoing Safety

Patients are active participants in the long-term safety system, not passive recipients. The most important things a patient can do include:

  • attend scheduled reviews, even when feeling well

  • bring up side effects, including ones that may feel minor

  • report changes in mood, mental health, or behaviour

  • update the practitioner about any new medications, including those prescribed by other clinicians

  • update the practitioner about new health conditions or significant life changes

  • contact the practitioner promptly when something unusual happens, rather than waiting

Patients can also contribute to the national safety system by reporting side effects to the TGA, either directly through tga.gov.au or through their prescriber or pharmacist. Reports do not need to prove a connection between the medication and the symptom; the role of the reporter is to describe what happened.

How the Picture Can Change Over Time

A practical point that often surprises patients is that information about a medication can update during the course of their treatment. New safety information from real-world use can lead to:

  • updated Consumer Medicine Information leaflets

  • new warnings or precautions in the Product Information document

  • changes to prescribing advice from clinical organisations

  • new monitoring recommendations

  • changes to the conditions under which the medication is supplied

A patient on long-term medication may find that their prescriber raises a new point about safety, monitoring, or precautions at a review, even if nothing has changed about the patient. This is the system working as intended. It is not a sign that something has gone wrong. The same process applies to every medication on the Australian market.

Frequently Asked Questions

Is it safe to take weight loss medication for years?

This depends on the specific medication, the individual patient, and the clinical context. The Consumer Medicine Information leaflet, available through tga.gov.au, and the prescribing practitioner are the authoritative sources for any specific medication.

What happens if I want to stop?

Patients should speak with the prescriber before stopping a prescribed medication. Some medications need to be stopped gradually, and a practitioner can advise on what is appropriate. The conversation also gives the practitioner a chance to review the broader plan.

How often will I be reviewed?

The schedule depends on the medication and the individual. A practitioner will agree a review schedule and explain what it covers. Patients should expect reviews to be part of the plan, not an optional add-on.

Can a pharmacist help me with safety questions between appointments?

Yes. The dispensing pharmacist is an independent clinician in the patient's care and can answer questions about side effects, interactions, and how to take a medication correctly. The pharmacist cannot change the prescription.

Where can I report a problem?

To the TGA through tga.gov.au, or via the prescriber, the dispensing pharmacist, or NPS MedicineWise. Reports help build the safety picture across the population.

What is the black triangle next to some medications?

The black triangle symbol indicates that the medicine is under additional monitoring by the TGA, which is common for newer medicines or for medicines being used in new ways. It signals that adverse event reporting is particularly valuable for those medicines. It is not a warning that something is wrong.

Will my practitioner know if safety information changes?

Yes. Australian prescribers receive updates through the TGA, NPS MedicineWise, professional bodies including the RACGP, and continuing professional development. Patients should also feel comfortable asking their practitioner if there is anything new they should be aware of.

Further Information

For authoritative Australian information on long-term safety, monitoring, and post-market surveillance, useful sources include:

  • The Therapeutic Goods Administration (tga.gov.au), including the Database of Adverse Event Notifications and the Black Triangle Scheme

  • The Consumer Medicine Information leaflet and Product Information document for the specific medication, available through tga.gov.au

  • NPS MedicineWise (nps.org.au)

  • Healthdirect Australia (healthdirect.gov.au)

  • The Australian Health Practitioner Regulation Agency (ahpra.gov.au)

This article is general information only and does not replace individualised medical advice. Decisions about long-term use of any medication should be made with a registered Australian healthcare practitioner who knows the patient's situation.

Back to Healthcare blog